Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Chao Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2981-5890; OpenAlex author ID A5039545222, A5048032919. Sources: OpenAlex.

Their work

Papers
11 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Prognostic value of multiparameter [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00259-025-07491-w↗
  2. Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary stu… Co-author DOI 10.1007/s00259-024-06943-z↗
  3. Integrated 68 Ga-FAPI-04 PET/MR in Pancreatic Cancer : Prediction of Tumor Response and Tumor Resectability After Neoadjuvant Therapy. Co-author DOI 10.1097/rlu.0000000000005300↗
  4. A multidomain fusion model of radiomics and deep learning to discriminate between PDAC and AIP based on 18F-FDG PET/CT images. Co-author DOI 10.1007/s11604-022-01363-1↗
  5. A Case of Pancreatic Cancer With Rare Cutaneous and Muscle Metastases on 18 F-FDG PET/CT Imaging. Last author DOI 10.1097/rlu.0000000000004699↗
  6. Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer. Co-author DOI 10.1007/s00259-022-05729-5↗
  7. Prognostic Evaluation Based on Dual-Time 18F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic Cancer Treated by Stereotactic Body Rad… First author DOI 10.1155/2022/6528865↗
  8. Prognostic evaluation based on dual time 18F-FDG PET/CT radiomics features in patients with locally advanced pancreatic cancer treated by Stereotactic Body Rad… First author DOI 10.21203/rs.3.rs-1357369/v2↗
  9. Radiomics model of dual-time 2-[18F]FDG PET/CT imaging to distinguish between pancreatic ductal adenocarcinoma and autoimmune pancreatitis. Co-author DOI 10.1007/s00330-021-07778-0↗
  10. Radiomics analysis for the differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma in 18 F-FDG PET/CT. First author DOI 10.1002/mp.13733↗
  11. [Differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma based on multi-modality texture features in 18F-FDG PET/CT]. First author DOI 10.7507/1001-5515.201807012↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changjing Zuo · 10 shared papers, 2019–2026 · strength 1.74
  2. Shiwei Guo · 4 shared papers, 2023–2026 · strength 1.01
  3. Zhaobang Liu · 6 shared papers, 2019–2023 · strength 0.84
  4. Zeyu Zhang · 3 shared papers, 2023–2026 · strength 0.77
  5. Gang Jin · 3 shared papers, 2024–2026 · strength 0.75
  6. Weiwei Su · 2 shared papers, 2025–2026 · strength 0.51
  7. Xiaodong Yang · 4 shared papers, 2019–2022 · strength 0.48
  8. Kai Cao · 2 shared papers, 2022–2024 · strength 0.39
  9. Guorong Jia · 2 shared papers, 2022–2023 · strength 0.33
  10. Gaofeng Sun · 3 shared papers, 2019–2021 · strength 0.33
  11. Shengnan Ren · 2 shared papers, 2021–2022 · strength 0.28
  12. Haojun Chen · 1 shared paper, 2026 · strength 0.26
  13. Yu-Chao Li · 1 shared paper, 2026 · strength 0.26
  14. Zeyu Zhang · 1 shared paper, 2024 · strength 0.24
  15. Wenting Wei · 1 shared paper, 2023 · strength 0.18
  16. Fei Wang · 1 shared paper, 2022 · strength 0.17
  17. Fei Wang · 1 shared paper, 2022 · strength 0.16
  18. Tao Wang · 1 shared paper, 2022 · strength 0.15
  19. Zeyu Zhang · 1 shared paper, 2022 · strength 0.15
  20. Jian Yang · 1 shared paper, 2022 · strength 0.15
  21. Yuquan Zhang · 1 shared paper, 2019 · strength 0.11
  22. Yuquan Zhang · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.